Rapid dose escalation with quetiapine: A pilot study

Journal of Clinical Psychopharmacology

Volumn 25, Issue 4, 2005, Pages 331-335

  Smith, Mark A ^a   McCoy, Robin ^a   Hamer Maansson, Jennifer ^a   Brecher, Martin ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; QUETIAPINE;

ADULT; AGITATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; HYPOTENSION; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PILOT STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 23044468574     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000168486.14516.7c     Document Type: Article

References (15)

1. Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Prize study group. Int Clin Psychopharmacol. 2000;15:121-131.
2. Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ici 204,636, 'seroquel') and haloperidol in schizophrenia. Psychol Med. 2000;30:95-105.
3. McConville B, Carrero L, Sweitzer D, et al. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol. 2003;13:73-80.
4. Arvanitis LA, Miller BG. Multiple fixed doses of "seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The seroquel trial 13 study group. Biol Psychiatry. 1997;42:233-246.
5. Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res. 2002;33:562-565.
6. Shaw JA, Lewis JE, Pascal S, et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol. 2001;11:415-424.
7. Hamner MB, Arvanitis LA, Miller BG, et al. Plasma prolactin in schizophrenia subjects treated with seroquel (ici 204,636). Psychopharmacol Bull. 1996;32:107-110.
8. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. Seroquel study group. J Clin Psychopharmacol. 1996;16:158-169.
9. Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther. 2002;24:21-37.
10. Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res. 2002;53:239-248.
11. Purdon SE, Malla A, Labelle A, et al. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci. 2001;26:137-149.
12. Fabre LF Jr., Arvanitis L, Pultz J, et al. ICI204,636: a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther. 1995;17:366-378.
13. Arango C, Bobes J. Managing acute exacerbations of schizophrenia: focus on quetiapine. Curr Med Res Opin. 2004;20:619-626.
14. Keks N, Tonso M, Tabone K, et al. Experience with atypical antipsychotics in an acute inpatient unit. Schizophr Res. 2003;60(1):289.
15. Cutler AJ, Goldstein JM, Tumas JA. Dosing and switching strategies for quetiapine fumarate. Clin Ther. 2002;24:209-222.